Entering text into the input field will update the search result below

Omeros collaborates University of Cambridge

  • Omeros Corporation (NASDAQ:OMER) has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR).
  • The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), and to OMS906, a human monoclonal antibody targeting MASP-3.
  • OMS721 is currently in three Phase 3 clinical programs – stem cell transplant-associated thrombotic microangiopathy, IgA nephropathy and atypical hemolytic uremic syndrome – and OMS906 is planned to enter the clinic in early 2020. Omeros holds proprietary positions around both MASP-2 and MASP-3.

Recommended For You

About OMER Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
OMER--
Omeros Corporation